OPKO Health (OPK) Launches RAYALDEE in the U.S.

November 23, 2016 11:36 AM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

OPKO Health, Inc. (Nasdaq: OPK) announced that it will commence shipments of RAYALDEE (calcifediol) extended-release capsules to distributors in the United States on Tuesday, November 29, 2016. The product will be available nationwide at retail pharmacies as early as Wednesday, November 30, 2016.

The U.S. launch of RAYALDEE follows the successful introduction of the product to thousands of nephrologists attending the American Society of Nephrology (ASN) Kidney Week Meeting last week in Chicago. RAYALDEE was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2016.

“The RAYALDEE launch represents a major milestone for OPKO,” commented Phillip Frost, M.D., CEO and Chairman of OPKO. “RAYALDEE is the first product developed by OPKO to be commercialized by our own marketing and sales teams, and represents an important contribution to the care of patients with chronic kidney disease. Based on the highly positive reception of RAYALDEE by nephrologists attending the recent ASN meeting, we believe that RAYALDEE will become a mainstay in the armamentarium of treatment options available for kidney disease patients.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

PDUFA

Add Your Comment